Ran An, Weiying Bao, Zeying Yan, Haimin Sun, Xiaoqian Xu, Sujiang Zhang
{"title":"Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.","authors":"Ran An, Weiying Bao, Zeying Yan, Haimin Sun, Xiaoqian Xu, Sujiang Zhang","doi":"10.1007/s00277-025-06310-4","DOIUrl":null,"url":null,"abstract":"<p><p>There has been a growing concern regarding the adverse events including hematological malignancies which occurring in the later stages following CAR-T immunotherapy. Here, we presented a case of secondary MDS/AML following CAR-T immunotherapy in our center. This refractory/relapsed MM patient who received systematic treatment including chemotherapy and targeted drug as well as autologous stem cell transplantation was developed into MDS and AML especially after BCMA CAR-T immunotherapy, and even allogeneic hematopoietic stem cell transplantation could not save the very poor prognosis. Further meta-analysis also demonstrated the considerable heterogeneity through the total studies CD19 and BCMA CAR-T subgroups. In conclusion, it is imperative that long-term and close monitoring for patients undergoing CAR-T immunotherapy, with particular attention to the potential development of hematological malignancies.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06310-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
There has been a growing concern regarding the adverse events including hematological malignancies which occurring in the later stages following CAR-T immunotherapy. Here, we presented a case of secondary MDS/AML following CAR-T immunotherapy in our center. This refractory/relapsed MM patient who received systematic treatment including chemotherapy and targeted drug as well as autologous stem cell transplantation was developed into MDS and AML especially after BCMA CAR-T immunotherapy, and even allogeneic hematopoietic stem cell transplantation could not save the very poor prognosis. Further meta-analysis also demonstrated the considerable heterogeneity through the total studies CD19 and BCMA CAR-T subgroups. In conclusion, it is imperative that long-term and close monitoring for patients undergoing CAR-T immunotherapy, with particular attention to the potential development of hematological malignancies.
期刊介绍：
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
